Takeda Discontinues Involvement In Matuzumab After Phase II Failure
This article was originally published in PharmAsia News
Executive Summary
Takeda will no longer jointly pursue development of cancer monoclonal antibody matuzumab because the epidermal growth factor receptor antagonist failed to meet primary endpoints in a Phase II trial, the Osaka, Japan-based company announced Feb. 18